Levetiracetam and N-Cadherin Antibody Alleviate Brain Pathology Without Reducing Early Epilepsy Development After Focal Non-convulsive Status Epilepticus in Rats.
N-cadherin antibody
antiepileptic drugs
epilepsy
levetiracetam
non-convulsive status epilepticus
seizures
synaptic proteins
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
11
2020
accepted:
04
02
2021
entrez:
15
3
2021
pubmed:
16
3
2021
medline:
16
3
2021
Statut:
epublish
Résumé
Focal non-convulsive status epilepticus (fNCSE) is a neurological condition characterized by a prolonged seizure that may lead to the development of epilepsy. Emerging experimental evidence implicates neuronal death, microglial activation and alterations in the excitatory and inhibitory synaptic balance as key features in the pathophysiology following fNCSE. We have previously reported alterations in the excitatory adhesion molecule N-cadherin in rats with fNCSE originating from the hippocampus that subsequently also develop spontaneous seizures. In this study, fNCSE rats were treated intraperitoneally with the conventional anti-epileptic drug levetiracetam in combination with intraparenchymal infusion of N-cadherin antibodies (Ab) for 4 weeks post-fNCSE. The N-cadherin Ab was infused into the fornix and immunohistochemically N-cadherin Ab-stained neurons were detected within the dorsal hippocampal structures as well as in superjacent somatosensory cortex. Continuous levetiracetam treatment for 4 weeks post-fNCSE reduced microglia activation, including cell numbers and morphological changes, partly decreased neuronal cell loss, and excitatory post-synaptic scaffold protein PSD-95 expression in selective hippocampal structures. The additional treatment with N-cadherin Ab did not reverse neuronal loss, but moderately reduced microglial activation, and further reduced PSD-95 levels in the dentate hilus of the hippocampus. Despite the effects on brain pathology within the epileptic focus, neither monotherapy with systemic levetiracetam nor levetiracetam in combination with local N-cadherin Ab administration, reduced the amount of focal or focal evolving into bilateral convulsive seizures, seizure duration, or interictal epileptiform activity during 1 month of continuous electroenephalogram recordings within the hippocampus after fNCSE. Behavioral tests for spatial memory, anxiety, social interaction and anhedonia did not detect gross behavioral differences between fNCSE rats with or without treatment. The results reveal the refractory features of the present rodent model of temporal lobe epilepsy following fNCSE, which supports its clinical value for further therapeutic studies. We identify the persistent development of epilepsy following fNCSE, in spite of partly reduced brain pathology within the epileptic focus.
Identifiants
pubmed: 33716930
doi: 10.3389/fneur.2021.630154
pmc: PMC7943745
doi:
Types de publication
Journal Article
Langues
eng
Pagination
630154Informations de copyright
Copyright © 2021 Avdic, Ahl, Andersson and Ekdahl.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Neuropsychopharmacology. 2005 Oct;30(10):1883-94
pubmed: 15798779
Epilepsia. 2003 Dec;44(12):1585-7
pubmed: 14636332
J Physiol. 2003 Feb 1;546(Pt 3):859-67
pubmed: 12563010
Neurobiol Dis. 2015 Feb;74:194-203
pubmed: 25461978
Epilepsia. 2004 Apr;45(4):314-21
pubmed: 15030493
BMC Neurosci. 2010 Jan 27;11:9
pubmed: 20105316
Epilepsy Behav. 2004 Apr;5(2):180-91
pubmed: 15123019
Lancet Neurol. 2004 Nov;3(11):663-72
pubmed: 15488459
Neurosci Biobehav Rev. 2004 Sep;28(5):497-505
pubmed: 15465137
Hippocampus. 2014 Aug;24(8):943-962
pubmed: 24753442
PLoS One. 2015 Jul 15;10(7):e0132366
pubmed: 26177381
PLoS One. 2012;7(4):e35557
pubmed: 22539981
Front Neurol. 2013 Nov 04;4:172
pubmed: 24204362
Cell Mol Immunol. 2018 Apr;15(4):414-417
pubmed: 29082919
Epileptic Disord. 2015 Jun;17(2):101-16
pubmed: 25905906
Epilepsy Res. 2004 Feb;58(2-3):167-74
pubmed: 15120747
Behav Genet. 1999 May;29(3):177-85
pubmed: 10547924
Eur J Neurosci. 2001 Mar;13(6):1113-24
pubmed: 11285009
Neuropsychiatr Dis Treat. 2008 Jun;4(3):507-23
pubmed: 18830435
Psychopharmacology (Berl). 2002 Mar;160(3):233-44
pubmed: 11889492
Neuropharmacology. 2000 Mar 3;39(5):777-87
pubmed: 10699444
Neurobiol Dis. 2004 Mar;15(2):196-205
pubmed: 15006689
Psychol Bull. 1976 May;83(3):482-504
pubmed: 17582919
Neurocrit Care. 2006;5(1):71-8
pubmed: 16960300
Dialogues Clin Neurosci. 2008;10(1):39-45
pubmed: 18472483
Behav Brain Res. 2004 Jun 4;152(1):67-79
pubmed: 15135970
Neurologia. 2019 May 7;:
pubmed: 31072691
Epilepsy Res. 2007 Mar;73(3):238-44
pubmed: 17161587
Neurology. 2002 Apr 23;58(8 Suppl 5):S27-39
pubmed: 11971130
Neurosci Biobehav Rev. 1997 May;21(3):309-26
pubmed: 9168267
Eur J Pharmacol. 1993 Mar 2;232(2-3):147-58
pubmed: 8467854
Epilepsia. 2010 Apr;51(4):671-5
pubmed: 19732133
Neuropharmacology. 2010 Mar-Apr;58(4-5):793-8
pubmed: 20026136
Childs Nerv Syst. 2014 Jun;30(6):1001-9
pubmed: 24526342
Pharmacol Res. 1995 Jul-Aug;32(1-2):1-13
pubmed: 8668641
Epilepsy Behav. 2011 Dec;22(4):617-40
pubmed: 22056342
Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13915-20
pubmed: 15358863
Epilepsy Res. 2015 Dec;118:34-48
pubmed: 26600369
Brain Plast. 2016 Jun 29;1(2):215-221
pubmed: 29765843
Nature. 2008 Oct 16;455(7215):903-11
pubmed: 18923512
Electroencephalogr Clin Neurophysiol. 1972 Mar;32(3):281-94
pubmed: 4110397
Ann N Y Acad Sci. 1969 Jul 30;159(3):852-9
pubmed: 5260302
Arch Int Pharmacodyn Ther. 1977 Oct;229(2):327-36
pubmed: 596982
Brain. 1966 Sep;89(3):499-530
pubmed: 5922048
PLoS One. 2013;8(1):e54105
pubmed: 23382872
Eur J Neurosci. 2006 Feb;23(4):965-74
pubmed: 16519661
Eur J Pharmacol. 1998 Jul 24;353(2-3):191-206
pubmed: 9726649
Front Neurol. 2019 Jul 02;10:701
pubmed: 31333561
Epilepsia. 2018 May;59(5):945-958
pubmed: 29637555
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13632-7
pubmed: 14581618
J Pharmacol Exp Ther. 1994 Apr;269(1):15-21
pubmed: 7909556
Science. 2005 Feb 25;307(5713):1324-8
pubmed: 15681343
Neurorehabil Neural Repair. 2013 Nov-Dec;27(9):878-88
pubmed: 23812605
Ther Adv Neurol Disord. 2008 Jul;1(1):13-24
pubmed: 21180561
Mol Brain. 2013 May 12;6:23
pubmed: 23663753
Epilepsia. 2002 Apr;43(4):350-7
pubmed: 11952764
Trends Neurosci. 2008 Sep;31(9):487-94
pubmed: 18684518
Brain Res. 2015 May 22;1608:225-34
pubmed: 25770058
Front Behav Neurosci. 2009 Jan 27;3:1
pubmed: 19194528